Related Experiment Video
Updated: Apr 27, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
[Association of CYP1A1 Ile462Val polymorphisms with susceptibility to small cell lung cancer]
Objective:
To investigate the association of Ile462Val polymorphisms of cytochrome P450 1A1 (CYP1A1) gene with small cell lung cancer susceptibility.
Methods:
A case-control study was done in 275 patients with small cell lung cancer and 406 control subjects. Genotypes of CYP1A1 Ile462Val were determined by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). Logistic regression analysis was performed to estimate odd ratios (ORs) and 95% confidence intervals (95% CI) associated with genetic variants of CYP1A1.
Results:
A case-control analysis showed ORs of 0.65 (95% CI 0.48 - 0.91) and 0.60 (95% CI 0.32 - 0.97) for small cell lung cancer in the CYP1A1 462 Ile/Val and 462 Val/Val genotype carriers respectively, compared with 462 Ile/Ile carriers. When stratified by smoking status, the ORs of 462 Ile/Val or Val/Val genotype for nonsmokers and smokers were 0.99 (95% CI 0.62 - 1.51) and 0.42 (95% CI 0.26 - 0.65), respectively. Furthermore, for light and heavy smokers, the ORs of 462 Ile/ Val or Val/Val genotype were 0.42 (95% CI 0.21 - 0.85) and 0.44 (95% CI 0.24 - 0.82), respectively.
Conclusion:
CYP1A1 Ile462Val polymorphisms may contribute to the decreased susceptibility of small cell lung cancer.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase